BACKGROUND AND OBJECTIVES: Deletion and methylation of the 9p21 chromosomal region are frequent in childhood acute lymphoblastic leukemia (ALL) but the prognostic significance is controversial. They inactivate CDKN2A, a gene encoding both p16INKa and p14ARF and, in some cases, contiguous genes that may influence chemosensitivity, such as CDKN2B encoding p15INKb or MTAP encoding methylthioadenosine phosphorylase. DESIGN AND METHODS: CDKN2A inactivation by deletion or methylation was studied using gene dosage and methyl-specific polymerase chain reaction. RESULTS: Bi-allelic and mono-allelic inactivation were found in, respectively, 38 (17%) and 31 (14%) of 227 children with B-lineage ALL enrolled in EORTC trials. Although CDKN2A inactivation was more often associated with poor prognostic features in B-lineage ALL, it failed to influence the outcome of the patients significantly. Bi-allelic CDKN2B and MTAP co-inactivation were found in 36 (16%) and 24 (11%) of patients, respectively, and did not influence the 6-year event-free survival rate either, even when the analysis was restricted to CDKN2A inactivated ALL. INTERPRETATION AND CONCLUSIONS: In this study of 227 cases of childhood B-lineage ALL, inactivation of CDKN2A, CDKN2B and MTAP did not influences the patients' outcome.
BACKGROUND AND OBJECTIVES: Deletion and methylation of the 9p21 chromosomal region are frequent in childhood acute lymphoblastic leukemia (ALL) but the prognostic significance is controversial. They inactivate CDKN2A, a gene encoding both p16INKa and p14ARF and, in some cases, contiguous genes that may influence chemosensitivity, such as CDKN2B encoding p15INKb or MTAP encoding methylthioadenosine phosphorylase. DESIGN AND METHODS: CDKN2A inactivation by deletion or methylation was studied using gene dosage and methyl-specific polymerase chain reaction. RESULTS: Bi-allelic and mono-allelic inactivation were found in, respectively, 38 (17%) and 31 (14%) of 227 children with B-lineage ALL enrolled in EORTC trials. Although CDKN2A inactivation was more often associated with poor prognostic features in B-lineage ALL, it failed to influence the outcome of the patients significantly. Bi-allelic CDKN2B and MTAP co-inactivation were found in 36 (16%) and 24 (11%) of patients, respectively, and did not influence the 6-year event-free survival rate either, even when the analysis was restricted to CDKN2A inactivated ALL. INTERPRETATION AND CONCLUSIONS: In this study of 227 cases of childhood B-lineage ALL, inactivation of CDKN2A, CDKN2B and MTAP did not influences the patients' outcome.
Authors: Amy L Sherborne; Fay J Hosking; Rashmi B Prasad; Rajiv Kumar; Rolf Koehler; Jayaram Vijayakrishnan; Elli Papaemmanuil; Claus R Bartram; Martin Stanulla; Martin Schrappe; Andreas Gast; Sara E Dobbins; Yussanne Ma; Eamonn Sheridan; Malcolm Taylor; Sally E Kinsey; Tracey Lightfoot; Eve Roman; Julie A E Irving; James M Allan; Anthony V Moorman; Christine J Harrison; Ian P Tomlinson; Sue Richards; Martin Zimmermann; Csaba Szalai; Agnes F Semsei; Daniel J Erdelyi; Maja Krajinovic; Daniel Sinnett; Jasmine Healy; Anna Gonzalez Neira; Norihiko Kawamata; Seishi Ogawa; H Phillip Koeffler; Kari Hemminki; Mel Greaves; Richard S Houlston Journal: Nat Genet Date: 2010-05-09 Impact factor: 38.330
Authors: Beatriz Rosales-Rodríguez; Juan Carlos Núñez-Enríquez; Juan Manuel Mejía-Aranguré; Haydeé Rosas-Vargas Journal: Curr Oncol Rep Date: 2020-11-14 Impact factor: 5.075
Authors: Hitoshi Ohtani; Andreas D Ørskov; Alexandra S Helbo; Linn Gillberg; Minmin Liu; Wanding Zhou; Johanna Ungerstedt; Eva Hellström-Lindberg; Weili Sun; Gangning Liang; Peter A Jones; Kirsten Grønbæk Journal: Cancer Res Date: 2020-04-03 Impact factor: 12.701
Authors: Charles G Mullighan; Xiaoping Su; Jinghui Zhang; Ina Radtke; Letha A A Phillips; Christopher B Miller; Jing Ma; Wei Liu; Cheng Cheng; Brenda A Schulman; Richard C Harvey; I-Ming Chen; Robert J Clifford; William L Carroll; Gregory Reaman; W Paul Bowman; Meenakshi Devidas; Daniela S Gerhard; Wenjian Yang; Mary V Relling; Sheila A Shurtleff; Dario Campana; Michael J Borowitz; Ching-Hon Pui; Malcolm Smith; Stephen P Hunger; Cheryl L Willman; James R Downing Journal: N Engl J Med Date: 2009-01-07 Impact factor: 91.245